Levofloxacino Kabi

Levofloxacin, the active ingredient in Levofloxacino Kabi, is a fluoroquinolone presented as an injectable solution for intravenous use. It treats a range of bacterial infections in adults, including community‑acquired pneumonia, complicated urinary tract infections, skin and soft‑tissue infections, acute bacterial sinusitis, and severe infections caused by susceptible Gram‑negative organisms.

GNH USA supplies Levofloxacino Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levofloxacino Kabi, a fluoroquinolone antibacterial, is indicated for several serious bacterial infections.

Community‑acquired pneumonia: effective in achieving clinical cure and microbiological eradication. Complicated urinary tract infection: resolves infection and prevents recurrence. Skin and soft‑tissue infections: reduces lesion size and eliminates pathogenic bacteria. Acute bacterial sinusitis: alleviates symptoms and clears infection. Severe Gram‑negative infections: provides bactericidal activity against susceptible strains.

Levofloxacino Kabi may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Rash - Elevated liver enzymes

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation - Severe hypersensitivity reactions (anaphylaxis) - Clostridioides difficile‑associated diarrhea - Peripheral neuropathy - Seizures

When using Levofloxacino Kabi, several precautions should be observed to minimize risks.

Assess renal function: adjust dose in patients with impaired clearance. Monitor for tendon pain: discontinue if signs of tendinitis or rupture appear. Check cardiac status: avoid in patients with known QT prolongation. Avoid use in pregnancy unless essential: category C, potential fetal risk. Avoid in breastfeeding unless benefits outweigh risks. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levofloxacino Kabi can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Concurrent use with non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal bleeding. - Co‑administration with drugs that prolong QT interval (e.g., quinidine, amiodarone): heightened risk of cardiac arrhythmias. - Combination with systemic corticosteroids: elevated risk of tendon rupture. - Use with antacids containing aluminum or magnesium: reduces levofloxacin absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Theophylline: increased plasma levels, monitor for toxicity. - Cyclosporine: may increase levofloxacin concentrations, adjust dose if needed.